Integrative study of multiple myeloma genetics and disease biology
Official title: Integrative Oncogenomics of Multiple Myeloma
Funded at Dana-Farber Cancer Inst · NIH-11535381 · Data updated 2026-11-12
A team at Dana-Farber and partners is pursuing a long-term project to understand the genetic and molecular drivers of multiple myeloma and how treatments interact with disease biology.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | December 1, 2011 |
| Project end | July 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $161,714 |
| NIH project number | 3P01CA155258-14S1 |
| Project ID | NIH-11535381 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with multiple myeloma who have or may achieve MRD negativity and participate in related clinical studies and sample collection.
✕Less likely to help
Patients not eligible for the clinical studies or lacking access to the required samples or sequencing analyses may not benefit.
What this research studies
This program brings together basic scientists and clinicians to map the genomic and epigenomic changes in multiple myeloma and to see how therapies like high-dose treatment affect patients who achieve minimal residual disease negativity. They have built new sequencing tools, analyzed how cancer cells evolve over time, and created a public data analysis portal to share findings. The work aims to identify when high-dose therapy helps and to develop better risk models based on molecular data. This is a multi-institution effort leveraging patient samples and complex genomic analyses to guide future therapies.
Why it matters
Potential benefit: If successful, the research could lead to more effective, personalized treatments and better prediction of which patients will benefit from specific therapies.
How similar studies have gone: Prior work has defined MRD roles and identified genomic targets, with ongoing efforts building on these advances.
Where this research is happening
-
Dana-Farber Cancer Inst
Boston, United States Active
Researchers
- Principal investigator: Munshi, Nikhil C. — Dana-Farber Cancer Inst
- Study coordinator: Munshi, Nikhil C.
Related research
Other NIH-funded projects on the same topics.
-
Comparative Modeling to Prevent, Detect Early, and Treat Multiple Myeloma
A research team will build and compare computer models to understand how multiple myeloma develops, can be detected earlier, and treated more effectively.
-
How LDL Affects Multiple Myeloma: New Pathways to Keep Remission
A new grant is studying how cholesterol from LDL particles fuels multiple myeloma and how this interaction influences the tumor environment and immune response, with goals to help patients stay in remission.
-
Therapy-induced senescence and immune activation in multiple myeloma
A study in people with multiple myeloma will explore how treatment-related senescence in cancer cells may stimulate the immune system and affect cancer return after standard frontline therapy.
-
BCMA CAR-T enteritis: understanding immune toxicities in multiple myeloma
A broad study to uncover why some CAR-T cell treatments targeting BCMA cause severe intestinal inflammation in people with multiple myeloma.
-
Understanding Drug-Resistant Multiple Myeloma to Stop Relapse
Researchers are studying why some myeloma cells resist treatment and how to create new therapies to prevent relapse.
-
Overcoming resistance to CART cell therapy in multiple myeloma
This grant aims to improve CAR T-cell therapy for people with multiple myeloma by tackling why some patients stop responding, using innovative approaches to boost cancer-fighting cells in the bone marrow.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.